Anti-Coagulants - EU-27

EU-27

In the EU-27, the Anti-Coagulants market is anticipated to witness a significant growth in revenue, with projections indicating a staggering amount of US$4.26bn in 2024.
This growth is expected to continue, with an estimated annual growth rate (CAGR 2024-2029) of 7.20%, leading to a substantial market volume of US$6.03bn by 2029.
When compared globally, it is worth noting that United States will dominate the market, generating the highest revenue of US$16,740.00m in 2024.
The EU-27 is experiencing a growing demand for direct oral anticoagulants due to their convenience and lower risk of bleeding compared to traditional warfarin therapy.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in EU-27 has been steadily growing over the past few years due to various reasons.

Customer preferences: Patients in EU-27 are increasingly opting for anti-coagulants over traditional blood thinners due to their ease of use and lower risk of complications. Anti-coagulants are also being preferred by physicians due to their effectiveness in preventing blood clots.

Trends in the market: The market for anti-coagulants in EU-27 is being driven by the increasing prevalence of cardiovascular diseases and the growing aging population. The demand for newer and more effective anti-coagulants is also on the rise. However, the market is being hindered by the high cost of these drugs and the availability of cheaper alternatives.

Local special circumstances: In countries like Germany and France, the market for anti-coagulants is being driven by the increasing prevalence of atrial fibrillation and deep vein thrombosis. In the UK, the market is being driven by the growing aging population and the increasing incidence of stroke. In Spain and Italy, the market is being driven by the increasing prevalence of cardiovascular diseases.

Underlying macroeconomic factors: The healthcare spending in EU-27 is expected to increase due to the growing aging population and the increasing prevalence of chronic diseases. This is expected to drive the demand for anti-coagulants in the region. However, the market is being hindered by the increasing cost of drug development and the pressure to reduce healthcare costs. The ongoing COVID-19 pandemic has also impacted the market, with delays in drug development and clinical trials.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.